Veraxa Biotech is trading at $1.90 (5.6%) up in pre-market, rebounding modestly after last week’s steady declines.
- The gain appears aligned with broader risk-on sentiment as major U.S. equity futures and tech-related shares trade higher ahead of key macro data and earnings.
- There are no fresh company-specific headlines or filings currently linked to the upward move.